Alto Neuroscience, Inc.
ANRO
$24.63
$0.100.41%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -14.11% | 19.91% | -16.72% | 0.21% | 9.43% |
| Total Depreciation and Amortization | -4.27% | -2.96% | -1.17% | 0.59% | 39.34% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -14.03% | 13.76% | -20.57% | 62.27% | -11.07% |
| Change in Net Operating Assets | 61.91% | 0.15% | 127.80% | -4,806.06% | -96.45% |
| Cash from Operations | -16.11% | 28.02% | 16.77% | -27.15% | -11.04% |
| Capital Expenditure | -- | -- | 100.00% | 95.26% | 49.65% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | 100.00% | 95.26% | 49.65% |
| Total Debt Issued | -100.00% | -- | -100.00% | -- | -100.00% |
| Total Debt Repaid | -- | -- | 100.00% | -- | -- |
| Issuance of Common Stock | 32,809.80% | -- | -100.00% | 304.08% | -26.87% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -222.35% | 212.27% | -- | -- |
| Cash from Financing | 32,700.65% | -75.04% | -93.28% | 18,526.53% | -96.28% |
| Foreign Exchange rate Adjustments | 75.00% | -33.33% | 86.36% | -466.67% | 185.71% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 495.82% | 25.82% | -76.17% | 44.51% | -17.96% |